Survey on the use of premix insulin analogues in diabetes mellitus type 1 and 2 in Mexico

Fernando Lavalle; Pedro García; Rutila Castañeda; Carlos Escalante; Juan Rosas; Héctor García Alcalá; Oded Stempa Blumenfeld; Ricardo Reynoso Mendoza; Luis Felipe Sánchez A; Rafael Real; Horacio Meza Bernardino; Mariano Beltrán Adame; Carlos Herrera Madrigal; Juan Villagordoa Mesa; Eduardo Garza Tamez; Leobardo Sauque Reyna; Gerardo Palafox Castelán; Ma Guadalupe Castro Martínez; José de Jesús Ríos González; Miguel Agustín Madero; Antonio Escalante Herrera; Rubén Aurelio Puebla Peralta; Luis Gerardo Rodríguez Torres; Francisco Javier Serrano; Alejandro Correa Flores; Ignacio Martínez Delgado; Víctor Manuel Michel; Juan Carlos Sienra Pérez; Alicia Yépez Rodríguez; Alfredo López Ponce; Orlando Solís Durán; Adriana Leticia Valdez González; Héctor Montiel Falcón; Héctor Andrés León Zárate; Sigfrido Miracle López; Ricardo Salas Flores; Guillermo González Gálvez; José Luis Hernández Pétriz; Manuel González Ortiz; Alejandro Sosa Caballero; José Alberto Rojas Jiménez; Carlos Ortega González; Margarita Barrientos Pérez; Marielita Vidrio Velázquez; Ester Rodríguez Sánchez; Perla Carrillo González; Raquel Noemí Faradji Hazán; Luis Ignacio Mejía Solís; Gilberto Mauricio Leguízamo; Sergio Godínez Gutiérrez; Patricia Leonor Pérez Sánchez; José Rodríguez Moctezuma

2012, Number 1

Med Int Mex 2012; 28 (1)

Survey on the use of premix insulin analogues in diabetes mellitus type 1 and 2 in Mexico

Lavalle F, García P, Castañeda R, Escalante C, Rosas J, García AH, Stempa BO, Reynoso MR, Sánchez ALF, Real R, Meza BH, Beltrán AM, Herrera MC, Villagordoa MJ, Garza TE, Sauque RL, Palafox CG, Castro MMG, Ríos GJJ, Madero MA, Escalante HA, Puebla PRA, Rodríguez TLG, Serrano FJ, Correa FA, Martínez DI, Michel VM, Sienra PJC, Yépez RA, López PA, Solís DO, Valdez GAL, Montiel FH, León ZHA, Miracle LS, Salas FR, González GG, Hernández PJL, González OM, Sosa CA, Rojas JJA, Ortega GC, Barrientos PM, Vidrio VM, Rodríguez SE, Carrillo GP, Raquel Noemí Faradji HRN, Mejía SLI, Mauricio LG, Godínez GS, Pérez SPL, Rodríguez MJ

Full text

How to cite this article

Language: Spanish
References: 22
Page: 7-15
PDF size: 273.77 Kb.

ABSTRACT

Background: There are several publications related to the use of premixed insulin analogs in Type 1 and 2 Diabetes Mellitus, however, there was no information about its use in the Mexican clinical practice.
Materials and methods: A survey was conducted to 48 physicians experts in Diabetes Mellitus. They were endocrinologists (62%), Internists (32) and diabetologists (6%).
Results: Twenty-four percent of the specialists pointed out that more than half of the patients who consult by the first time do not respond to treatment with oral hypoglycemic medication. A high number of patients treated with insulin reach glycemic control goals. Most of the experts treat more than half of their patients with insulin. Sixty-six percent of the experts use premixed insulin analogs in their patients with type 1 Diabetes, and a high percentage use them in type 2 Diabetes. Most of the expert physicians recommend the use of premixed insulin analogs as the first line treatment in their patients diagnosed with Type 2 Diabetes.
Conclusions: Premixed insulin analogs are widely accepted by patients because they offer a complete coverage of their metabolic requirements, reducing the number of daily injections. In type 1 Diabetes, premixed insulin analogs will be used to improve metabolic control and to strengthen compliance. This document describes the use of premixed insulin analogs in the treatment of Diabetes Mellitus in Mexico.

REFERENCES

Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28(2):260-265.
IDF. Atlas de Diabetes. 4a ed.
Mertens I, VGLF, New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. J Thromb Haemost 2006;4(5):11646.
Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993-2006. Salud Pública Mex 2010;52 suppl 1:S72-S79.
Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368 (9548):1673-1679.
Ramachandran A, Snehalatha C, Yamuna A, et al. Costeffectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007;30(10):2548-2552.
Standards of medical care in diabetes-2008. Diabetes Care 2008;31 Suppl 1:S12-54.
Genuth S, Eastman R, Kahn R, et al. Implications of the United Kingdom prospective diabetes study. Diabetes Care 2003;26 Suppl 1:S28-32.
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29(8):1963-1972.
UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-865.
The Diabetes Control and Complications Trial Research G. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med 1993;329(14):977-986.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-1589.
A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999;16(9):716-730.
Sicras-Mainar A, Navarro-Artieda R, Rejas-Gutiérrez J, et al. Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain. BMC Fam Pract 2007;8:60.
DECODE Study Group, Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161(3):397-405.
Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164(19):2090-2095.
Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NID: the Diabetes Intervention Study, 11-year follow-up. Diabetología 1996; 39(12):1577-1583.
Meigs JB, Nathan DM, D’Agostino RB S, et al. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25(10): 845-850.
Bulsara MK, Holman EA Davis DA, et al. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care 2004;27(10):2293-2298.
Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28(2):260-265.
Clements M, Tits J, Kinsley BT, et al. Improved glycaemia control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes, Obesity and Metabolism 2008;10(3): 229-237.
Nathan DM, Buse JB, Davidson MB, et al. Medical management of Hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of Diabetes. Diabetes care 2009;31(1):193-203.